Loading clinical trials...
Loading clinical trials...
A Phase I Study of the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers
Conditions
Interventions
Placebo
Foralumab Nasal
Locations
1
United States
Ann Romney Center for Neurologic Diseases
Boston, Massachusetts, United States
Start Date
November 12, 2018
Primary Completion Date
July 23, 2019
Completion Date
November 9, 2020
Last Updated
March 17, 2025
NCT07256522
NCT04592640
NCT04854278
NCT07253896
NCT06244537
NCT05583006
Lead Sponsor
Tiziana Life Sciences LTD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions